Ademi LLP is investigating whether the proposed acquisition of Pacira (NASDAQ: PCRX) by Viatris, provides fair value to Pacira’s public shareholders and whether Pacira’s Board adequately protected shareholder interests in negotiating and approving the transaction.
What Is Ademi LLP Investigating?
- The exchange ratio and whether it adequately reflects Pacira’s value and future prospects;
- Substantial change-of-control benefits available to Pacira insiders in connection with the transaction;
- Restrictions on competing transactions, including a significant termination penalty that may discourage another potential buyer from making a superior proposal; and
- The conduct of Pacira’s Board of Directors in negotiating and approving the transaction and whether the Board fulfilled its duties to public shareholders.